Bioharvest Stock Price, News & Analysis

BioHarvest Sciences Inc. (NASDAQ: BHST) has secured a new CDMO (Contract Development and Manufacturing Organization) contract to develop a plant-based fragrance compound from a threatened plant species. The company will utilize its Botanical Synthesis technology platform and AI-assisted research capabilities for this project targeting the multi-billion-dollar fragrance market.

The Stage 1 contract focuses on developing cell banks for future production of targeted fragrance molecules, with milestone-based payments. Upon successful completion, Stage 2 would involve compound production in liquid media. This agreement expands BioHarvest's CDMO portfolio beyond pharmaceuticals and nutrition into the fragrance industry while contributing to rare plant species conservation.

BioHarvest Sciences (NASDAQ: BHST) has successfully completed Stage 1 of its CDMO contract with an unnamed Nasdaq-listed pharmaceutical company and is advancing to Stage 2. The project, which began in early 2024, demonstrates the capability of BioHarvest's Botanical Synthesis platform to develop active pharmaceutical compounds.

In Stage 1, BioHarvest's research team successfully isolated target plant cells and replicated them using their proprietary platform. Stage 2 will focus on producing sufficient biomass for testing and developing optimal growing conditions in liquid media. Upon success, the project will progress to small and medium-scale production before moving to commercial volume production.

BioHarvest Sciences (NASDAQ: BHST), a pioneer in Botanical Synthesis technology, will release its Q1 2025 financial results on May 15, 2025, after market close. The company will host an investor conference call and webcast at 4:30 p.m. Eastern time on the same day.

Management will discuss quarterly results, provide a corporate update, and hold a Q&A session. The conference call can be accessed via U.S./Canada dial-in (1-877-300-8521) or International dial-in (1-412-317-6026) using Conference ID 2552254. A telephone replay will be available through May 29, 2025.

BioHarvest Sciences (NASDAQ: BHST) reported strong Q4 2024 financial results with revenues growing 62% to $7.3 million, exceeding guidance. Full-year 2024 revenues increased 99% to $25.2 million with gross margins expanding 1,000 basis points to 55%.

Key highlights include a CDMO partnership with Tate & Lyle for plant-based sweeteners development, successful Nasdaq Global Market uplisting, and VINIA® subscribers surpassing 50,000. The company launched VINIA® SuperFood tea line following successful coffee line introduction which generated $2.3 million since December 2023.

Q4 gross profit increased 80% to $4.1 million (56.7% margin), while marketing expenses decreased to 40.4% of revenue. Management projects Q1 2025 revenues of at least $7.8 million and expects adjusted EBITDA breakeven in H2 2025. The company ended Q4 with $2.4 million cash, subsequently raising $3.9 million in debt financing.

BioHarvest Sciences (NASDAQ: BHST) has scheduled its Q4 and full year 2024 earnings release for March 31, 2025, after market close. The company will host an investor conference call and webcast at 4:30 p.m. Eastern time on the same day.

The earnings call will include a discussion of financial results, corporate updates, and a Q&A session. Participants can join using U.S./Canada dial-in (1-844-825-9789) or International dial-in (1-412-317-5180) with Conference ID 10197712. A replay will be available through April 14, 2025, using pin number 10197712.

BioHarvest Sciences (NASDAQ: BHST) has announced its participation in the 37th Annual Roth Conference, scheduled for March 16-18, 2025, at the Laguna Cliffs Marriott Resort & Spa in Dana Point, CA. CEO Ilan Sobel will conduct one-on-one meetings with institutional investors throughout the event.

The company, which pioneers the patented Botanical Synthesis technology platform, views this as a significant opportunity to showcase its growth trajectory. Following their Nasdaq listing and the launch of their CDMO Services Division, BioHarvest has achieved notable milestones, including:

• VINIA product reaching $50 Million in cumulative sales
• Advancement in CDMO Services division research for plant-based solutions
• Partnerships with pharmaceutical, nutraceutical, cosmetics, and nutrition sectors

BioHarvest Sciences (NASDAQ: BHST) has announced promising in vitro test results for their proprietary Olive Cell compound, showing reduced fat accumulation in human liver cells. The compound, rich in Verbascoside, demonstrated effectiveness in mitigating fat accumulation in liver steatosis and fibrosis models.

The development targets Non-Alcoholic Fatty Liver Disease (NAFLD), which affects 30-40% of U.S. adults, with its severe form NASH impacting 3-5% of the adult population. The company plans to launch the Olive Cell product as a nutraceutical in 2026, while exploring pharmaceutical partnerships.

The tests, conducted on human hepatic cells, showed the compound's ability to reduce collagen type 1 levels in XL-2 cells. This product will join VINIA® in BioHarvest's portfolio, which has already achieved over $50M USD in sales with 50,000+ active subscribers.

BioHarvest Sciences (NASDAQ: BHST) announced that sales of its flagship product VINIA, a red grape cell-based supplement, have exceeded $50 million USD in cumulative sales. The majority of these sales occurred since the US launch less than 4 years ago.

The company has achieved over 50,000 active U.S. users on recurring subscription packages, with VINIA receiving approximately 8,000 customer reviews and a verified rating of 4.8/5. Clinical trials have demonstrated VINIA's ability to improve blood flow and arterial dilation.

To support future growth, BioHarvest plans to expand its production capacity by 4x with a new 100-ton per year facility, expected to be operational in late 2026. The company has invested 15 years and over $100M in developing its patented Botanical Synthesis technology, which is now being used in their CDMO Services division for pharmaceutical and nutrition industry partners.